Clinical trial • Phase III • Infectious Disease
EV25 for Influenza
Phase III trial of EV25 for Influenza. 16 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Influenza
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 20-03-2026
- First CTIS Authorization Date
- 30-04-2026
Trial design
Phase III trial across 1 site in Belgium.
- Target Sample Size
- 16
Eligibility
Recruits 16 Vulnerable population selected; no details on consent or assent provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the record.
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 1
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 16
Belgium
- Earliest CTIS Part Ii Submission Date
- 20-04-2026
- Latest Decision Or Authorization Date
- 30-04-2026
- Processing Time Days
- 10
- Number Of Sites
- 1
- Number Of Participants
- 16
Sites
- Site Name
- SGS Belgium
- Department Name
- SGS - Clinical Research
- Contact Person Name
- Thomas De Ridder
- Contact Person Email
- thomas.deridder@sgs.com
- Number Of Participants
- 16
Sponsor
Primary sponsor
- Full Name
- Eradivir Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- EV25
Related trials
Other published trials that may interest you.
- INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2); INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN; A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN for Influenza
- INFLUENZA VIRUS B/AUSTRIA/1359417/2021 - LIKE STRAIN; INFLUENZA VIRUS A/VICTORIA/4897/2022 (H1N1)PDM09 - LIKE STRAIN; INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2)-LIKE STRAIN for Influenza
- INFLUENZA A (H1N1/WSN/1933) NUCLEOPROTEIN FUSED TO C-TERMINAL FRAGMENTS OF TWO AVIAN C4BP ALFA CHAIN SEQUENCES for Influenza
- INFLUENZA VIRUS B/AUSTRIA/1359417/2021 - LIKE STRAIN; INFLUENZA VIRUS A/VICTORIA/4897/2022 (H1N1)PDM09 - LIKE STRAIN; INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2)-LIKE STRAIN for Influenza
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection